ENTITY

Ascentage Pharma Group Corp (6855 HK)

37

Analysis

Health Care • China

Ascentage Pharma Group International operates as a clinical-stage biotechnology company. The Company develops novel therapies for cancers, hepatitis B virus, age-related diseases, and more. Ascentage Pharma Group International conducts businesses in China, the United States, and other countries.

more

Refresh

Exchange Announcement • 28 Nov 2024 16:30

Voluntary Announcement - New Indication Of Olverembatinib Included Into China 2024 National Reimbursement Drug List

Exchange Announcement • 25 Nov 2024 08:04

List Of Directors And Their Roles And Functions

Exchange Announcement • 25 Nov 2024 07:59

Appointment Of Independent Non-Executive Directors

Exchange Announcement • 17 Nov 2024 18:13

Voluntary Announcement - Ascentage Pharma Announces A New Drug Application For Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted And Recommended Priority Review Designation By Cde Of China'S Nmpa

Exchange Announcement • 06 Nov 2024 08:17

Voluntary Announcement - Ascentage Pharma To Present Results From Multiple Clinical Studies Of Olverembatinib, Lisaftoclax, Apg-5918 And Apg-2449 At The 2024 American Society Of Hematology (Ash) Annual Meeting, Two Of Which Have Been Selected For Oral Reports

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x